Nona is leveraging advantages of Harbour Mice technology to achieve this; Harbour Mice generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. The company hopes to deveop next-generation drugs by integrating Harbour Mice with highly robust antibody screening platforms.